

or research use only. Not for use in diagnostic procedures.

For Research Use Only (RUO)

C

Xpert[®] NPM1 Mutation Assay

Joseph H Memor

Mark McCov



↓ The Need

Current testing options for NPM1 are not only cumbersome, but also expensive and time consuming for the lab to implement because:

- Available testing methods are complex and create inefficient laboratory workflows.
- No international scale has been established for NPM1 monitoring, so laboratories are dependent on ratios and must run laborious standard curves.

↓ The Solution

Leveraging Cepheid's **Lab in a Cartridge™** technology, the Xpert® NPM1 Mutation assay decreases workflow complexity and hands-on time by automating the entire testing process, delivering faster results.

The Xpert NPM1 Mutation assay is a quantitative assay for the NPM1 mutation transcripts (types A,B and D in exon 12) as a ratio of NPM1 Mutation/ABL1. It provides high assay sensitivity, standardization, and on-demand molecular results in about 3 hours. With minimal hands-on time and a streamlined workflow, the Xpert NPM1 Mutation assay eliminates the need for time consuming hands-on processes and enables researchers to run NPM1 testing in-house.

Easy to Use

- < 3 hours total testing process
- Simply add treated blood sample and an off-board reagent to the Xpert test cartridge

Robust Design

- Includes two internal controls
- 4 mL input volume of whole blood supports high assay sensitivity for detection of low-level transcripts

Coverage, plus **Accuracy**, plus **Peace of mind**

That's the **PCR***plus* advantage. From Cepheid.

↓ The Impact

- · Clinical Researcher: Same day information
- Laboratory: Flexibility and simplicity for a more streamlined workflow

Move your lab forward

- Decrease costs: Eliminate need for standard curve and replicate testing
- Optimize lab organization: Free up technician time for other lab activities
- Provide flexibility: Process any number of samples, any day of the week, with a fixed cost per sample
- · Simplify reporting: Deliver information on concise one-page report

Technical Performance

Linearity was evaluated independently for each of the three subtypes, mutA, mutB and mutD, using cell lysates that were specific for a high level of either the mutA, mutB or mutD subtype. Lysate from each high level of NPM1 mutation cell line was diluted in a background lysate prepared from AML-negative sample to target ranges of ~2000% to 0.01% NPM1 Mutation/ ABL. The panel members, including the negative level, were tested on one assay kit lot in replicates of 4. Testing and statistical analyses were conducted in accordance with CLSI EP06-A. Linear regression analyses were performed for first, second and third order polynomials. The results for each subtype were considered linear if the polynomial regression coefficients were insignificant (p-values > 0.05). If p-values for the polynomial regression coefficients are < 0.05, then the maximum absolute difference at any level between higher order and linear predictions should be < 0.3 LR (corresponding to a 2-fold difference).

Linear Regression Curves for Subtype Transcript mutA





Catalog Information

Xpert[®] NPM1 Mutation Assay

10 tests

.....

RNPM1-10

.....

References: Xpert NPM1 Mutation RUO IFU ENGLISH 302-5822 Rev. B

CORPORATE HEADQUARTERS 904 Caribbean Drive Sunnyvale, CA 94089 USA

 TOLL FREE
 +1.888.336.2743

 PHONE
 +1.408.541.4191

 FAX
 +1.408.541.4192

EUROPEAN HEADQUARTERS w Vira Solelh 81470 Maurens-Scopont France PHONE +33.563.82.53.00 FAX +33.563.82.53.01 EMAIL cepheid@cepheideurope.fr ©

www.Cepheid.com

europe.fr © 2022–2023 Cepheid. 0910-03